These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 22359236)

  • 21. Cost-effectiveness of 70-gene MammaPrint signature in node-negative breast cancer.
    Chen E; Tong KB; Malin JL
    Am J Manag Care; 2010 Dec; 16(12):e333-42. PubMed ID: 21291290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Head-to-head comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of compliance.
    Retèl VP; Joore MA; van Harten WH
    Breast Cancer Res Treat; 2012 Jan; 131(2):627-36. PubMed ID: 21947677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group*
    Genet Med; 2016 Aug; 18(8):770-9. PubMed ID: 26681310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness analysis of multigene expression profiling assays to guide adjuvant therapy decisions in women with invasive early-stage breast cancer.
    Hannouf MB; Zaric GS; Blanchette P; Brezden-Masley C; Paulden M; McCabe C; Raphael J; Brackstone M
    Pharmacogenomics J; 2020 Feb; 20(1):27-46. PubMed ID: 31130722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer.
    El Ouagari K; Karnon J; Delea T; Talbot W; Brandman J
    Breast Cancer Res Treat; 2007 Jan; 101(1):37-49. PubMed ID: 16821085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the U.K.
    Holt S; Bertelli G; Humphreys I; Valentine W; Durrani S; Pudney D; Rolles M; Moe M; Khawaja S; Sharaiha Y; Brinkworth E; Whelan S; Jones S; Bennett H; Phillips CJ
    Br J Cancer; 2013 Jun; 108(11):2250-8. PubMed ID: 23695023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Commercialized multigene predictors of clinical outcome for breast cancer.
    Ross JS; Hatzis C; Symmans WF; Pusztai L; Hortobágyi GN
    Oncologist; 2008 May; 13(5):477-93. PubMed ID: 18515733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation.
    Biroschak JR; Schwartz GF; Palazzo JP; Toll AD; Brill KL; Jaslow RJ; Lee SY
    Breast J; 2013; 19(3):269-75. PubMed ID: 23614365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. US insurance program's experience with a multigene assay for early-stage breast cancer.
    Hornberger J; Chien R; Krebs K; Hochheiser L
    Am J Manag Care; 2011 May; 17(5 Spec No):e194-202. PubMed ID: 21711071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.
    Ward S; Scope A; Rafia R; Pandor A; Harnan S; Evans P; Wyld L
    Health Technol Assess; 2013 Oct; 17(44):1-302. PubMed ID: 24088296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer.
    Berdunov V; Millen S; Paramore A; Hall P; Perren T; Brown R; Griffin J; Reynia S; Fryer N; Longworth L
    J Med Econ; 2022; 25(1):591-604. PubMed ID: 35416089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer?
    Lamond NW; Skedgel C; Younis T
    Expert Rev Pharmacoecon Outcomes Res; 2013 Apr; 13(2):243-50. PubMed ID: 23570435
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.
    Hornberger J; Cosler LE; Lyman GH
    Am J Manag Care; 2005 May; 11(5):313-24. PubMed ID: 15898220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective cost-effectiveness analysis of genomic profiling in breast cancer.
    Retèl VP; Joore MA; Drukker CA; Bueno-de-Mesquita JM; Knauer M; van Tinteren H; Linn SC; van Harten WH
    Eur J Cancer; 2013 Dec; 49(18):3773-9. PubMed ID: 23992641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor-positive, lymph-node-negative early-stage breast cancer in Japan.
    Yamauchi H; Nakagawa C; Yamashige S; Takei H; Yagata H; Yoshida A; Hayashi N; Hornberger J; Yu T; Chao C; Yoshizawa C; Nakamura S
    BMC Health Serv Res; 2014 Sep; 14():372. PubMed ID: 25190451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A cost-effectiveness analysis of axillary node dissection in postmenopausal women with estrogen receptor-positive breast cancer and clinically negative axillary nodes.
    Orr RK; Col NF; Kuntz KM
    Surgery; 1999 Sep; 126(3):568-76. PubMed ID: 10486611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective?
    Naeim A; Keeler EB
    Breast Cancer Res Treat; 2005 Nov; 94(2):95-103. PubMed ID: 16261407
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
    Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
    Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.
    Ross JS
    Adv Anat Pathol; 2009 Jul; 16(4):204-15. PubMed ID: 19546609
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical roundtable monograph: a multidisciplinary approach to the use of oncotype DX in clinical practice.
    Gradishar WJ; Hansen NM; Susnik B
    Clin Adv Hematol Oncol; 2009 Apr; 7(4):1-7. PubMed ID: 19536946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.